IP Library Granted Patent US 11,278,886
Granted Patent B2
US 11,278,886 · App. 16/416,761 · Granted Mar 22, 2022

Assay device and reader

Inventors: Phillip Lowe (Stirling, GB); Steven Alexander Keatch (Stirling, GB); Brian McGuigan (Stirling, GB)
Assignee: LumiraDx UK Ltd.
B01L3/502715B01L3/527G01N33/54326G01N33/54386G01N35/0098B01L7/00B01L2200/027B01L2200/0668B01L2200/0684B01L2200/10B01L2300/0609B01L2300/0645B01L2300/0654B01L2300/0816B01L2400/043B01L2400/0487B01L2400/0688
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,278,886
App. No.
16/416,761
Granted
Mar 22, 2022
Kind
B2
Abstract

The present invention relates to a microfluidic based assay system, comprising a disposable assay cartridge and associated reading device, as well as the individual components themselves. The present invention also relates to methods of conducting assays, using the cartridge and device of the invention, as well as kits for conducting assays.

Claims (21)

1. An assay system for conducting an assay on a liquid sample, the assay system comprising:

(a) a microfluidic cartridge comprising:

(i) a sandwich comprising a top layer of substrate, a bottom layer of substrate, and one or more microfluidic channels including at least one detection area disposed therebetween,

(ii) a magnetic binding agent and a fluorescently labeled binding agent disposed within said channel(s), wherein (a) the magnetic binding agent comprises a first binding moiety coupled to a magnetic or paramagnetic particle, (b) the fluorescently labeled binding agent comprises a second, different binding moiety coupled to a fluorescent label, and (c) the first binding moiety and the second binding moiety bind an analyte to be detected so that, if analyte is present, the magnetic binding agent, the analyte, and the fluorescently labeled binding agent form a complex comprising the magnetic binding agent, the analyte and the fluorescently labeled binding agent,

(iii) a sample inlet port for introducing said liquid sample into the cartridge

(iv) at least one port for allowing air to be vented from the one or more microfluidic channels of the cartridge, and

(v) wherein, prior to use in the system, the cartridge does not contain a wash liquid; and

(b) a reader device, the reader device comprising:

(i) a receiving port for introducing the cartridge into the reader,

(ii) a magnetic field generator configured to subject the cartridge to a magnetic field to retain the complexes within the detection area during an air wash,

(iii) a pump configured to perform the air wash to remove sample liquid from the detection area so that the complexes are retained in an air environment within the detection area following the air wash, and

(iv) a detector configured to facilitate fluorescent detection of analyte present within the one or more of the complex(es) in the air environment within the detection area following the air wash.

2. The assay system of claim 1 , wherein said one or more microfluidic channels within the microfluidic assay cartridge further comprise a stop feature comprising a hydrophobic material to prevent liquid sample from passing through the microfluidic channels by capillary action alone.

3. The assay system of claim 1 , wherein the pump is operative to move the liquid sample in either direction such that the liquid sample can be moved in a reciprocal motion within the cartridge.

4. The assay system of claim 1 , wherein the first and/or second binding moiety is an antibody, protein, peptide or oligonucleotide.

5. The assay system of claim 4 , wherein the first binding moiety is an antibody.

6. The assay system of claim 5 , wherein the second binding moiety is an antibody.

7. The assay system of claim 1 , wherein the detector is a fluorescence detector.

8. The assay system of claim 7 , wherein the first binding moiety is an antibody.

9. The assay system of claim 8 , wherein the second binding moiety is an antibody.

10. The assay system of claim 1 , wherein the magnetic field generator comprises a permanent magnet.

Assignments (5)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY, RECORDED ON MARCH 30, 2021 AT REEL/FRAME 055850/0771 Recorded Aug 5, 2024
From: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
To: LUMIRADX INTERNATIONAL LTD; LUMIRADX UK LTD
Reel/Frame 068327/0149 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Mar 30, 2021
From: LUMIRADX INTERNATIONAL LTD; LUMIRADX UK LTD
To: BIOPHARMA CREDIT PLC
Reel/Frame 055850/0771 →
CHANGE OF NAME Recorded Dec 30, 2020
From: MULTI-SENSE TECHNOLOGIES LIMITED
To: LUMIRADX TECHNOLOGY LTD
Reel/Frame 054773/0978 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 30, 2020
From: LOWE, PHILLIP; KEATCH, STEVEN ALEXANDER; MCGUIGAN, BRIAN
To: MULTI-SENSE TECHNOLOGIES LIMITED
Reel/Frame 054773/0980 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 30, 2020
From: LUMIRADX TECHNOLOGY LTD
To: LUMIRADX UK LTD
Reel/Frame 054774/0015 →